Yum! Brands Blows Up
October 7, 2015
The share price chart of Yum! Brands is shown above. The writing was on the wall. We warned about the impending collapse in Yum! Brands’ (YUM) shares in our highly-selective July 14 note, “Warning! 5 Heavily-Followed Dividend-Paying Stocks to Avoid:” “The owner of KFC, Pizza Hut and Taco Bell has a solid franchise, but its share price has rocketed too far too fast, perhaps on renewed speculation that it will spin off its Yum! China division into a separate entity, which may never happen. But while speculation fuels the share price advance, there are a few things we do know for certain. The fast-food environment in the US is cutthroat, and the trend toward fast-casual is a long-term secular dynamic,
Transaction Alerts: Moving Closer to Market Neutral on Energy
October 6, 2015
The Best Ideas Newsletter portfolio has generated significant outperformance in part from avoiding many of the landmines across the energy sector during the past many months. We’ve done equally well in our calls in the Dividend Growth Newsletter portfolio, and we’re very proud of raising the issue of the importance of looking at non-GAAP free cash flow across pipeline entities. We believe that such a measure is the best one to assess the timing of free cash flows as they are generated, an important consideration for investors of all types, and not properly addressed in measures of distributable cash flow or a company’s dividend or distribution. Why are we now inching ever so slightly back into energy? 1. The market
Attention to Pricing Issues Pressures Valeant
October 6, 2015
As recently as early August, Valeant Pharmaceuticals (VRX) was flying high, continuing its history of aggressively pursuing acquisitions and profiting greatly from newly-acquired drugs. However, exactly what had allowed the firm to grow at a substantial pace has caused a precipitous fall in its share price and may cause significant pressure to the biotech industry (IBB) as a whole in the relatively-near future, or so some are positing. Valeant has a reputation for growing through acquisitions and aggressively cutting costs during the integration of newly-acquired companies. Through the acquisitions of other biotech and pharmaceutical companies, Valeant becomes the owners of various drugs, of which it then has control over pricing. This is where the company, in the eyes of some
Time to Scoop Up More GE? Another Activist Stake in Yet Another Newsletter Portfolio Holding
October 5, 2015
Stocks in Valuentum’s newsletter portfolios–the Best Ideas Newsletter portfolio and Dividend Growth Newsletter portfolio–are often ones that find the greatest interest among activist investors. After all, they are generally undervalued on a discounted cash-flow basis, generate tremendous amounts of free cash flow, and have solid balance sheets, flush with cash that can be used to pay outsize dividends. This makes them ripe for shareholder activism, which so far, has been a blessing for constituents of the newsletter portfolios as share prices are driven higher. Traditionally, it has been Carl Icahn (IEP) that has taken a liking to our ideas. The activist investor, and chosen Treasury Secretary of Presidential hopeful Donald Trump, has been involved at one time or another in
Standard & Poor’s Notes Heightened Default Risks
October 5, 2015
Not all is well in Big Oil, or at least, not all is what it once was. The upstream oil and gas arena continues to face significant pressure from falling energy resource pricing, runaway capital spending projections and conditions that may not subside anytime soon. At the heart of the problem is OPEC’s strategy to maintain market share, apparently at all costs, which is different than the cartel’s efforts in previous cycles to support the price. Though upstream industry constituents have announced capital spending reductions and some have idled rigs, commercial inventories of crude oil remain at decade highs, and risks to the global economy, not the least of which from China (FXI), Brazil (EWZ), and Australia (EWA), threaten the
Seeking Alpha, Is It Time To End Anonymity?
October 5, 2015
Is this really what investors want to see? Isn’t it time to end anonomity on website postings and end the smear campaigns? Write to Eli Hoffman at eli@seekingalpha.com and George Moriarty at george@seekingalpha.com to express your concerns. What do you think? Is it time for a change?
Dividend Increases for the Week Ending October 2
October 4, 2015
Below we provide a list of firms that raised their dividends during the week ending October 2. The dividend reports of covered firms on this list will be updated shortly with the new information. To access our dividend reports use the ‘Symbol’ search box in our website header. Firms Raising Their Dividends This Week Adcare Health Systems (ADK): now $0.06 per share quarterly dividend, was $0.055. American Financial (AFG): now $0.28 per share quarterly dividend, was $0.25. Bank of the Ozarks (OZRK): now $0.145 per share quarterly dividend, was $0.14. Clarcor (CLC): now $0.22 per share quarterly dividend, was $0.20. DineEquity (DIN): now $0.92 per share quarterly dividend, was $0.875. Enterprise Products (EPD): now $0.385 per share quarterly dividend, was
Thank You for the Victory Lap Barron’s!
October 2, 2015
For those that saw the reference to our recent article in Barron’s and the unfortunate, derogatory counter-punch by another author, we appreciate the support and congratulations! The Barron’s article highlighting our work was a victory lap on our call on Kinder Morgan, or we think most should have interpreted it as such. The recognition was well-received by existing members and interested new members alike! How to interpret our call on Kinder Morgan >> As many of you know, however, the call on Kinder Morgan has been off the table for some time now. We had recently moved to “neutral” on Kinder Morgan (see here), after shares collapsed from $40 to $29, which is our current fair value estimate of the firm
Nelson Answers All of Your Questions on MLPs
October 1, 2015
Join the Forum: http://www.valuentum.com/forum/20
Understanding Your MLP’s Financially-Engineered Equity Value
October 1, 2015
For background on this topic, please read “5 Reasons Why Kinder Morgan Will Collapse,” and “5 More Reasons Why Kinder Morgan Will Collapse.” In this article, we will synthetically create the equivalent of a master limited partnership (MLP), called iNewCorp with Kinder Morgan’s financial profile, from scratch with effectively no capital at all, with only a strong credit rating. In such an example, we’ll also explain how valuation techniques cannot ignore growth capital in the valuation equation of MLPs or other midstream corporates by pricing them on a multiple of “distributable cash flow” or on the dividend/distribution that follows it. We’ll do so by contemplating the value of a company that has a “distributable cash flow” stream requiring maintenance (and/or
